CureVac N.V. has experienced a 3% increase in its shares premarket on Friday following the release of new data from a trial of its mRNA COVID-19 vaccine candidates, developed in collaboration with GSK PLC. The investigational monovalent shot and bivalent vaccine candidate have successfully elevated antibody levels and demonstrated good tolerability across various dosages, according to CureVac's statement. Notably, all three dose levels tested were lower than those currently used in mRNA-based COVID vaccines approved in the U.S. and European Union. CureVac is currently engaged in advanced discussions with regulators to pave the way for a phase 3 study of the vaccine candidates. Should they receive approval, these shots would become competitors to mRNA Covid vaccines already available from Moderna Inc. and Pfizer Inc.
Over the past 12 months, CureVac shares have experienced a decline of 34%, while the S&P 500 has shown a gain of 23%. GSK's American depositary receipts also saw a premarket decline of 0.5% on Friday, but have achieved an increase of 13.3% over the past year.
Our Latest News
Stellantis to Cut Jobs at Two Jeep Plants in the U.S.
Stellantis will implement job cuts at two Jeep plants in the U.S. as a result of California emissions regulations, affecting over 10,000 workers. This move alig...
Solar Stocks Surge as Prospect of Lower Interest Rates Boosts Sector
Solar stocks have surged following the Fed's indication of potential interest rate cuts, alleviating concerns about demand for solar panels. The industry still...
Big Lots Stock Downgraded Amid Financial Concerns
Loop Capital analyst downgrades Big Lots stock as the company faces a precarious financial situation and seeks new financing options. Stock is down 12% in prema...